The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients

Human Immunology

Volumn 70, Issue 3, 2009, Pages 139-145

  Sthoeger, Zev M ^a,b   Sharabi, Amir ^a   Dayan, Molly ^a   Zinger, Heidy ^a   Asher, Ilan ^b   Sela, Uri ^a   Mozes, Edna ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b KAPLAN HOSPITAL   (Israel)

Author keywords

Cytokine modulation; Human SLE; Immunomodulating peptide; Immunoregulatory T cells; Negative regulators

Indexed keywords

CASPASE 3; CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GLYCYLTYROSYLTYROSYLTRYPTOPHYLSERYLTRYPTOPHYLISOLEUCYLARGINYL GLUTAMINYLPROLYLPROLYLGLYCYLLYSYLGLYCYLGLUTAMYLGLUTAMYLTRYPTOPHYLISOLEUCYL GLYCINE; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; PREDNISONE; PROTEIN BCL XL; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ADULT; APOPTOSIS; COMPLEMENTARITY DETERMINING REGIONS; CYTOKINES; DOWN-REGULATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PEPTIDES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 61349192167     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.01.018     Document Type: Article

References (44)

1. Hahn B.H. An overview of the pathogenesis of systemic lupus erythematosus. In: Wallace D.J., and Hahn B.H. (Eds). Dubios' lupus erythematosus (2002), Lippincott Williams & Wilkins, Philadelphia 87-95
2. Nagy G., Koncz A., and Perl A. T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol 25 (2005) 123
3. Horowitz D.A., and Jacob C.O. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin Immumopathol 16 (1994) 181-200
4. Segal R., Bermas B.L., Dayan M., Kalush F., Shearer G.M., and Mozes E. Kinetics of cytokine production in experimental systemic lupus erythematosus: Involvement of T helper cell 1/T helper cell 2-type cytokines in disease. J Immunol 158 (1997) 3009-3016
5. Trébéden-Nègre H., Weill B., Fournier C., and Batteux F. B cell apoptosis accelerates the onset of murine lupus. Eur J Immunol 33 (2003) 1603-1612
6. Emlen W., Niebur J., and Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152 (1994) 3685-3692
7. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 (2004) 531-562
8. Paust S., and Cantor H. Regulatory T cells and autoimmune disease. Immunol Rev 204 (2005) 195-207
9. Sthoeger Z.M., Dayan M., Tcherniack A., Green L., Toledo S., Segal R., Elkayam O., and Mozes E. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin Exp Immunol 131 (2003) 385-392
10. Waisman A., Shoenfeld Y., Blank M., Ruiz P.J., and Mozes E. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int Immunol 7 (1995) 689-696
11. Waisman A., Ruiz P.J., Israeli E., Eilat E., Könen-Waisman S., Zinger H., Dayan M., and Mozes E. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc Natl Acad Sci USA 94 (1997) 4620-4625
12. Eilat E., Zinger H., Nyska A., and Mozes E. Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1- and CDR3-based peptides of a pathogenic autoantibody. J Clin Immunol 20 (2000) 268-278
13. Sela U., Dayan M., Hershkoviz R., Cahalon L., Lider O., and Mozes E. The negative regulators Foxj1 and Foxo3a are upregulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses. Eur J Immunol 36 (2006) 2971-2980
14. Luger D., Dayan M., Zinger H., Liu J.P., and Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 24 (2004) 579-590
15. Sharabi A., Zinger H., Zborowsky M., Sthoeger Z.M., and Mozes E. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by upregulating CD4+CD25+ cells and TGF-beta. Proc Natl Acad Sci USA 103 (2006) 8810-8815
16. Rapoport M.J., Sharabi A., Aharoni D., Bloch O., Zinger H., Dayan M., and Mozes E. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a downregulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin Immunol 117 (2005) 262-270
17. Sharabi A., Haviv A., Zinger H., Dayan M., and Mozes E. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared with dexamethasone: Different effects on cytokines and apoptosis. Clin Immunol 119 (2006) 146-155
18. Sharabi A., Luger D., Ben-David H., Dayan M., Zinger H., and Mozes E. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol 179 (2007) 4979-4987
19. Sharabi A., Azulai H., Sthoeger Z.M., and Mozes E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: Similarities and differences in the mechanisms of action. Immunology 121 (2007) 248-257
20. Sela U., Sharabi A., Dayan M., Hershkoviz R., and Mozes E. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models. Immunology (2008) In Press
21. Sthoeger Z.M., Zinger H., Dekel B., Arditi F., Reisner Y., and Mozes E. Lupus manifestations in severe combined immunodeficient (SCID) mice and in human/mouse radiation chimeras. J Clin Immunol 23 (2003) 91-99
22. Mauermann N., Sthoeger Z.M., Zinger H., and Mozes E. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 137 (2004) 513-520
23. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., Schaller J.G., Talal N., and Winchester R.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982) 1271-1277
24. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., and Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35 (1992) 630-640
25. Sthoeger Z.M., Chiorazzi N., and Lahita R.G. Regulation of the immune response by sex hormones. I. In vitro effects of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation. J Immunol 141 (1988) 91-98
26. Coffer P.J., and Burgering B.M. Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 4 (2004) 889-899
27. Dean G.S., Tyrrell-Price J., Crawley E., and Isenberg D.A. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 59 (2000) 243-251
28. Chan R.W., Lai F.M., Li E.K., Tam L.S., Chow K.M., Li P.K., and Szeto C.C. The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. Nephrol Dial Transplant 21 (2006) 1534-1540
29. Bijl M., Horst G., Limburg P.C., and Kallenberg C.G. Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): Relation to lymphocyte activation and disease activity. Lupus 10 (2001) 866-872
30. Letterio J.J., and Roberts A.B. Regulation of immune responses by TGF-beta. Annu Rev Immunol 16 (1998) 137-161
31. Ohtsuka K., Gray J.D., Stimmler M.M., Toro B., and Horwitz D.A. Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J Immunol 160 (1998) 2539-2545
32. Sfikakis P.P., Souliotis V.L., Fragiadaki K.G., Moutsopoulos H.M., Boletis J.N., and Theofilopoulos A.N. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 123 (2007) 66-73
33. Yaswen L., Kulkarni A.B., Fredrickson T., Mittleman B., Schiffman R., Payne S., Longenecker G., Mozes E., and Karlsson S. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood 87 (1996) 1439-1445
34. Lin S.C., Chen K.H., Lin C.H., Kuo C.C., Ling Q.D., and Chan C.H. The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest 37 (2007) 987-996
35. Baráth S., Soltész P., Kiss E., Aleksza M., Zeher M., Szegedi G., and Sipka S. The severity of systemic lupus erythematosus negatively correlates with the increasing number of CD4+CD25(high)FoxP3+ regulatory T cells during repeated plasmapheresis treatments of patients. Autoimmunity 40 (2007) 521-528
36. Valencia X., Yarboro C., Illei G., and Lipsky P.E. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 178 (2007) 2579-2588
37. Hahn B.H., Anderson M., Le E., and La Cava A. Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients. Arthritis Rheum 58 (2008) 2488-2497
38. Lin L., Hron J.D., and Peng S.L. Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a. Immunity 21 (2004) 203-213
39. Peng S.L. Foxo in the immune system. Oncogene 27 (2008) 2337-2344
40. Lin L., Spoor M.S., Gerth A.J., Brody S.L., and Peng S.L. Modulation of Th1 activation and inflammation by the NF-kappaB repressor Foxj1. Science 303 (2004) 1017-1020
41. Li C.S., Zhang Q., Lim M.K., Sheen D.H., Shim S.C., Kim J.Y., Lee S.S., Yun K.J., Moon H.B., Chung H.T., and Chae S.C. Association of FOXJ1 polymorphisms with systemic lupus erythematosus and rheumatoid arthritis in Korean population. Exp Mol Med 39 (2007) 805-811
42. Chawla-Sarker M., Linder D.J., Liu Y.F., Williams B.R., Sen G.C., Silverman R.H., and Borden E.C. Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8 (2003) 237-249
43. Goergescu L., Vakkalanka R.K., Elkon K.B., and Crow M.K. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by FasL. J Clin Invest 100 (1997) 2622-2633
44. Zheng S.G., Wang J.H., Gray J.D., Soucier H., and Horwitz D.A. Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: The role of IL-2, TGF-beta, and IL-10. J Immunol 172 (2004) 5213-5221